Article Details

Syngene International slides after Q2 FY22 PAT tumbles 21% to Rs 67 cr

Retrieved on: 2021-10-21 09:46:05

Tags for this article:

Click the tags to see associated articles and topics

Syngene International slides after Q2 FY22 PAT tumbles 21% to Rs 67 cr. View article details on hiswai:

Excerpt

During the quarter, we continued to manufacture remdesivir for COVID-19, under a voluntary licensing agreement from Gilead.".

Article found on: www.business-standard.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up